BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
UBS
Citi
Argus Health
US Department of Justice
Teva
Healthtrust
Mallinckrodt
Baxter
Federal Trade Commission

Generated: January 22, 2018

DrugPatentWatch Database Preview

Novo Nordisk Company Profile

« Back to Dashboard

Summary for Novo Nordisk
International Patents:466
US Patents:32
Tradenames:50
Ingredients:31
NDAs:41

Drugs and US Patents for Novo Nordisk

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc TRESIBA insulin degludec SOLUTION;SUBCUTANEOUS 203314-002 Sep 25, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc XULTOPHY 100/3.6 insulin degludec; liraglutide SOLUTION;SUBCUTANEOUS 208583-001 Nov 21, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLOG FLEXPEN insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-003 Jan 19, 2001 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLOG INNOLET insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-004 Apr 23, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc INNOFEM estradiol TABLET;ORAL 040312-001 Nov 19, 1999 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-011 Jan 23, 2015 RX No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLIN 70/30 insulin recombinant purified human; insulin susp isophane semisynthetic purified human INJECTABLE;INJECTION 019441-001 Jul 11, 1986 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NOVOLOG INNOLET insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 020986-004 Apr 23, 2004 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc NOVOLOG MIX 70/30 FLEXPEN insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-004 May 3, 2002 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novo Nordisk Inc VICTOZA liraglutide recombinant SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Novo Nordisk

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc LEVEMIR FLEXPEN insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536-002 Jun 16, 2005 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc LEVEMIR INNOLET insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536-003 Jun 16, 2005 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NOVOLOG MIX 70/30 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-001 Nov 1, 2001 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN FLEXPRO somatropin recombinant INJECTABLE;INJECTION 021148-008 Mar 1, 2010 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc VICTOZA liraglutide recombinant SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc LEVEMIR FLEXTOUCH insulin detemir recombinant INJECTABLE;SUBCUTANEOUS 021536-005 Oct 31, 2013 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN NORDIFLEX somatropin recombinant INJECTABLE;INJECTION 021148-006 Oct 1, 2004 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NORDITROPIN somatropin recombinant INJECTABLE;INJECTION 021148-003 Jun 20, 2000 ➤ Subscribe ➤ Subscribe
Novo Nordisk Inc NOVOLOG MIX 70/30 PENFILL insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021172-002 Nov 1, 2001 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NOVO NORDISK drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 18 mg/3 mL prefilled syringe ➤ Subscribe 12/12/2016
➤ Subscribe Vaginal Tablets 10 mcg ➤ Subscribe 1/2/2013
➤ Subscribe Tablets 1 mg/500 mg and 2 mg/500 mg ➤ Subscribe 4/9/2009

Non-Orange Book US Patents for Novo Nordisk

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,828,923 Insulin derivatives ➤ Subscribe
6,011,007 Acylated insulin ➤ Subscribe
9,616,180 Automatic injection device with a top release mechanism ➤ Subscribe
6,582,404 Dose setting limiter ➤ Subscribe
8,097,698 Derivatives of GLP-1 analogs ➤ Subscribe
8,357,120 Injection device with torsion spring and rotatable display ➤ Subscribe
6,869,930 Acylated insulin ➤ Subscribe
6,384,016 Stabilized aqueous peptide solutions ➤ Subscribe
7,226,990 Extendin derivatives ➤ Subscribe
8,096,978 Automatic injection device with a top release mechanism ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Novo Nordisk Drugs

Supplementary Protection Certificates for Novo Nordisk Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00021 Netherlands ➤ Subscribe PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623
2013 00030 Denmark ➤ Subscribe
2009004,C0770388 Lithuania ➤ Subscribe PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
2 Finland ➤ Subscribe
2013 00001 Denmark ➤ Subscribe PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3,7-DIHYDROPURIN-2,6-DION ENANTIOMERER OG SALTE DERAF - SAERLIGT LINAGLIPTIN - I KOMBINATION MED METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/12/780/001-028 20120720
496 Luxembourg ➤ Subscribe PRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1
2014026 Lithuania ➤ Subscribe PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
2014000071 Germany ➤ Subscribe PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116
2009 Austria ➤ Subscribe PRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103
00596 Netherlands ➤ Subscribe PRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001EU/1/12/807/004EU/1/12/807/005EU/1/12/807/007EU/1/12/807/008EU/1/12/807/009EU/1/12/807/012EU/1/12/807/013EU/1/12/807/015 2013210121
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Cerilliant
Express Scripts
Citi
US Department of Justice
Healthtrust
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot